By Fineline Cube 
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955) on Aug. 27, 2025 released its 2025 interim financial results and business update. The company reported RMB 393 million in total operating revenue, marking an 8 % year‑on‑year increase, while product sales revenue rose to RMB 385 million (+16 %). Boan Bio has now achieved profitability for three consecutive reporting periods, underscoring the strength of its commercial strategy.
Financial Highlights
| Metric | 2025 Interim | YoY Change |
|---|---|---|
| Operating Revenue | RMB 393 m | +8 % |
| Product Sales Revenue | RMB 385 m | +16 % |
| Profitability | 3‑year consecutive | – |
Commercial Momentum
- Approved Product Portfolio – Boan Bio currently markets four products, with three already commercialized.
- Sales Network – Over 3,000 hospitals and medical institutions nationwide constitute the company’s sales backbone.
- Marketing Excellence – An in‑house team of seasoned sales professionals and diversified strategic partnerships fuel the steady 16 % sales lift in the first half of the year.
R&D Pipeline & Funding
- Biologics License Application (BLA) – Two projects are under BLA review.
- Clinical & Early‑Stage Projects – More than 10 projects span from pre‑clinical to early‑phase clinical trials.
- Self‑Sustaining Model – Commercialization of the first wave of R&D products is establishing a stable, self‑sufficient revenue stream that will finance future drug development and accelerate innovation timelines.